Intra Cellular Therapies | ITCI - Acreedores Comerciales



Acreedores Comerciales Cambio Fecha
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
ALKERMES USD 107.95M 39.95M 2025-12
BioCryst Pharmaceuticals USD 15.83M 10.26M 2025-12
Biogen USD 432M 18.9M 2025-12
Bristol-Myers Squibb USD 4.29B 1.14B 2025-09
Cytokinetics USD 105.62M 83.53M 2025-12
Esperion Therapeutics USD 65.07M 12.44M 2025-12
Gilead Sciences USD 715M 93M 2025-12
Halozyme Therapeutics USD 20.9M 5.54M 2025-12
J&J USD 10.46B 1.53B 2026-03
Minerva Neurosciences USD 640K 305K 2025-12
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Novartis USD 4.46B 99M 2025-12
Prothena USD 5.88M 4.63M 2025-12
RedHill Biopharma USD 835K 7.03M 2025-06
Supernus Pharmaceuticals USD 107.8M 813K 2025-12
United Therapeutics USD 7.1M 460.9M 2025-12
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12